Torrent Pharma recalls 0.5 mg Anagrelide Capsules due to impurities detected in stability testing. This prescription medication may pose risks if used as intended.
“Torrent Pharma Anagrelide Capsules Recall: Impurities Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38022-torrent-pharma-anagrelide-capsules-recall-impurities-risk. Based on FDA recall #D-1862-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1862-2019%22&limit=1).
Torrent Pharma Inc. recalled Anagrelide Capsules, USP, 0.5 mg on Sept. 6, 2019, after the FDA announced high out-of-specification impurity results. The Food and Drug Administration issued the recall due to failed stability testing specifications.
How to tell if you have it
Brand: Torrent Pharma
Product: Anagrelide Capsules, USP, 0.5 mg
Packaging: 100-count bottle
NDC: 13668-453-01
Lot #: BFE2E003
Expiration: 08/31/2020
Quantity: 2,472 bottles
The hazard
The recall was triggered by high out-of-specification results for impurities detected during routine stability testing. The FDA classified the recall as Class II.
Context
GovInfoNow's records show Torrent Pharma Inc. has 14 other recalls on record since July 22, 2013. Other recent recalls of similar products include Torrent Fluoxetine Tablets 20mg Recall (May 27, 2025), Torrent Pantoprazole Tablets Recall (April 11, 2022), and Torrent Pharma recalls 200mg Carbamazepine tablets (Dec. 2, 2021). Other recent recalls of similar products include Ajanta Pharma Fluphenazine Tablets Recall (Aug. 25, 2026), Appco Pharma Prazosin Capsules Recall (March 27, 2026), and Somerset Therapeutics Dexamethasone Injection Recall (Feb. 4, 2026).
How to tell if you have this one
Check for the 0.5 mg Anagrelide Capsules, 100-count bottle, Rx only. Look for lot number BFE2E003 with expiration 08/31/2020.
Brand
Torrent Pharma
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Verify the product name, lot number, and expiration date to confirm if it's affected.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 14 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-1862-2019 (September 6, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1862-2019 to see it in context.
Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.